Clinical Trials

Find a Trial

Trial Summary

Protocol No.BTCRC-LUN16-081
Principal InvestigatorDurm, Greg
PhasePhase II
Age GroupAdult
TitlePhase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
DescriptionThis study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Histological or cytological confirmation of NSCLC. A pathology report confirming the diagnosis of NSCLC must be obtained and reviewed by the treating physician prior to registration to study.
  • Must have unresectable or inoperable stage IIIA or IIIB disease. Subjects must be considered unresectable or inoperable based on the judgment of the treating physician.
For a full list of participation criteria, please visit
Applicable Disease SitesLung
Participating InstitutionsIU Health Central Indiana Cancer Centers
    Indiana University (IU)
    • Eskenazi Hospital
    • Indiana University Hospital / IU Simon Cancer Center
    Roudebush VA Medical Center
    • Roudebush VA Medical Center
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632